Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA)

被引:20
作者
Murphy, Catriona [1 ]
Bennett, Kathleen [2 ]
Fahey, Tom [3 ]
Shelley, Emer [4 ]
Graham, Ian [5 ]
Kenny, Rose Anne [1 ]
机构
[1] Trinity Coll Dublin, Dept Med Gerontol, Dublin, Ireland
[2] Trinity Coll Dublin, Dept Pharmacol & Therapeut, Dublin, Ireland
[3] Royal Coll Surgeons Ireland, Sch Med, Dept Gen Practice, HRB Ctr Primary Care Res, Dublin 2, Ireland
[4] Hlth Serv Execut, Dept Publ Hlth, Dublin, Ireland
[5] Tallaght Hosp, Dept Cardiol, Dublin, Ireland
来源
BMJ OPEN | 2015年 / 5卷 / 07期
关键词
CORONARY-HEART-DISEASE; PREVENTION GUIDELINES; LIFE-STYLE; HEALTH; ADHERENCE; MEDICATION; THERAPY; PEOPLE; OLDER; CARE;
D O I
10.1136/bmjopen-2015-008017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: This study aims to examine the extent to which statins are used by adults at high risk of cardiovascular disease (CVD) compared to European clinical guidelines. The high-risk groups examined are those with (1) known CVD, (2) known diabetes and (3) a high or very high risk (>= 5%) of CVD mortality based on Systematic COronary Risk Evaluation (SCORE). Design: This study is cross-sectional in design using data from the first wave (2009-2011) of The Irish Longitudinal Study on Ageing (TILDA). Setting and participants: The sample (n=3372) is representative of community living adults aged 50-64 years in Ireland. Results: Statins were used by 68.6% (95% CI 61.5% to 75.8%) of those with known CVD, 57.4% (95% CI 49.1% to 65.7%) of those with known diabetes and by 19.7% (95% CI 13.0% to 26.3%) of adults with a SCORE risk >= 5%. Over a third (38.5%, 95% CI 31.0% to 46.0%) of those with known CVD, 46.8% (95% CI 38.4% to 55.1%) of those with known diabetes and 85.2% (95% CI 79.3% to 91.1%) of those with a SCORE risk >= 5% were at or above the low-density lipoprotein cholesterol (LDL-C) target of 2.5 mmol/L specified in the 2007 European guidelines. Conclusions: Despite strong evidence and clinical guidelines recommending the use of statins for secondary prevention, a gap exists between guidelines and practice in this cohort. It is also of concern that a low proportion of adults with a SCORE risk >= 5% were taking statins. A policy response that strengthens secondary prevention, and improves risk assessment and shared decision-making in the primary prevention of CVD is required.
引用
收藏
页数:9
相关论文
共 51 条
  • [1] Should people at low risk of cardiovascular disease take a statin?
    Abramson, John D.
    Rosenberg, Harriet G.
    Jewell, Nicholas
    Wright, James M.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2013, 347
  • [2] Statin prescribing in Northern Ireland and England pre and post introduction of the quality and outcomes framework
    Alabbadi, Ibrahim
    Crealey, Grainne
    Turner, Kathryn
    Rafferty, Therese
    Keenan, Lynn
    Murray, Penny
    McElnay, James C.
    [J]. PHARMACY WORLD & SCIENCE, 2010, 32 (01): : 43 - 51
  • [3] Amarenco P, 2006, NEW ENGL J MED, V355, P549
  • [4] [Anonymous], J PUBLIC HLTH OXF
  • [5] [Anonymous], EUR J PREV CARDIOL
  • [6] Auer J, 2014, EUR J PREV CARDIOL
  • [7] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    Baigent, C
    Keech, A
    Kearney, PM
    Blackwell, L
    Buck, G
    Pollicino, C
    Kirby, A
    Sourjina, T
    Peto, R
    Collins, R
    Simes, J
    [J]. LANCET, 2005, 366 (9493) : 1267 - 1278
  • [8] Heartwatch: a secondary prevention programme in primary care in Ireland
    Bennett, Kathleen
    Jennings, Siobhan
    Collins, Claire
    Boland, Michael
    Leahy, John
    Bedford, Declan
    Shelley, Emer
    [J]. EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2008, 15 (06): : 651 - 656
  • [9] Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -: The PRIMO study
    Bruckert, E
    Hayem, G
    Dejager, S
    Yau, C
    Bégaud, B
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2005, 19 (06) : 403 - 414
  • [10] The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
    Brugts, J. J.
    Yetgin, T.
    Hoeks, S. E.
    Gotto, A. M.
    Shepherd, J.
    Westendorp, R. G. J.
    de Craen, A. J. M.
    Knopp, R. H.
    Nakamura, H.
    Ridker, P.
    van Domburg, R.
    Deckers, J. W.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2009, 339 : 36